Adamis Pharmaceuticals Corp. (ADMP) stock prices were up by 0.91% shortly after market trading commenced on September 2nd, 2021. This brought the price per share up to USD$1.12 early on in the trading day.
ADMP Stock Commences Patient Dosing
September 2nd, 2021 saw ADMP stock announce the initiation of patient dosing in the Phase 2/3 clinical trial for Tempol in adult patients with confirmed Covid-19 infection. Preclinical studies have shown the oral antiviral product candidate to have shown antiviral, anti-inflammatory, and antioxidant activity. The clinical trial is designed to enroll a total of 248 patients. The timing of the trial is essential as the delta variant of the coronavirus spreads, with breakthrough infections in vaccinated individuals occurring in the U.S. and worldwide. The treatment is an antiviral and anti-inflammatory measure that could prove to fight the delta variant if it is proven safe and effective in the trial.
Tempol Study Development
The commencement of patient dosing in the Phase 2/3 clinical trial for Tempol comes after encouraging preclinical data in several disease models of infection and inflammation. Newer variants popping up all over the world with increased transmissibility and resistance necessitates the development of new therapeutic agents. Israel has one of the highest levels of Covid-19 vaccinations in the world, yet it is now indicating one of the world’s highest infection rates. The majority of the hospitalized patients in Israel are fully gene vaccinated. Approval of Tempol could result in the provision of a crucial drug for the treatment of Covid-19, thereby curbing the pandemic.
NIH Involvement
The National Institute of Health recently highlighted Tempol as a potential home treatment for Covid-19. The NIH concluded that the treatment would likely prevent severe disease. Recent studies conducted by NIH researchers indicate Tempol to have potent antiviral activity against the virus that causes Covid-19 in lab studies. The NIH news article also reports the treatment’s ability to reduce Covid-19 symptoms. This is done by calming inflammation, protecting organs from damage, and decreasing the clumping of platelets.
Future Outlook for ADMP Stock
The company generated strong momentum over the first half of the fiscal year 2021, which it has continued through the start of the first half. ADMP stock is poised to capitalize on the opportunities afforded to it as it develops its clinical study for Tempol. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value.
